Twice as Many Providers as in May Are Submitting 340B Drug Claims Data to 340B ESP, Pharma Contractor Says

340B ESP infographic
340B ESP says more that 1,000 covered entities—double the number in May—are submitting 340B drug claims data to it to be able to keep dispensing manufacturers’ drugs to patients at multiple contract pharmacies.

More than 1,000 covered entities—double the number in May—are submitting 340B drug claims data to Second Sight Solutions’ 340B ESP platform to be able to keep dispensing manufacturers’ drugs to patients at multiple contract pharmacies, a senior 340B ESP leader

Read More »

Breaking News

Effort Launched to Create 340C—a Separate Drug Discount Program for Health Centers and Possibly Other Entities

Advocates for Community Health wordmark
The health center advocacy group behind a proposed 340B program alternative recently slammed the 340B ACCESS Act, saying the newly introduced drug discount program overhaul bill would make it harder for members to leverage the 340B program and care for patients.

A national community health center association founded last year is launching a campaign to urge Congress to create a separate drug discount program called 340C open to health centers and perhaps rural hospitals and federal grantees.

According to a description

Read More »

Congressman Who Represents Virginia 340B Hospital Profiled by New York Times Is Exploring Oversight and Legislation

Richmond Community Hospital signage and building
U.S. Rep. A. Donald McEachin (D-Va.) is exploring legislative responses to a controversy over a health system's alleged neglect of a profitable 340B hospital in a predominantly Black neighborhood.

The congressman who represents Richmond, Va., told a health system Wednesday he rejects its reasons for ceasing intensive care, maternity, and other vital services at a Richmond hospital in a mainly Black neighborhood despite the hospital allegedly earning millions of

Read More »

With Elections Nearing, Biden Is Ordering HHS to do More to Drive Drug Costs Down

Joe Biden holding microphone
President Biden will sign an executive order today directing HHS to submit a plan in 90 days "to lower drug costs and promote access to innovative drug therapies for Medicare beneficiaries."

President Biden will sign an executive order today directing the U.S. Health and Human Services Department (HHS) “to consider additional actions to further drive down prescription drug costs,” the White House said this morning.

“Under the Executive Order, HHS will

Read More »

BIO CEO McMurry-Heath Steps Down Amid Reported Conflict with Board

Dr. Michelle McMurry-Heath headshot
BIO CEO Dr. Michelle McMurry-Heath has stepped down amid reports of ongoing dissension within the group over its direction.

Biotechnology Innovation Organization (BIO) on Monday announced the resignation of its CEO, molecular immunologist Dr. Michelle McMurry-Heath, after confirming over the weekend that she was on a leave of absence. BIO is the trade association and top lobbying group for

Read More »

Hospital Group Urges MedPAC to Drop Part B Pay-Cut Proposal, Cites 340B Impact

MedPAC chart of drugs add-on amounts
The AHA wants MedPAC to drop a Medicare Part B drug reimbursement policy option it is considering making to Congress on the grounds that it will hurt 340B hospitals.

The American Hospital Association is urging the Medicare Payment Advisory Commission to abandon a Medicare Part B drug reimbursement policy option it is considering making to Congress, arguing that the proposed change would hurt 340B hospitals’ ability to provide care

Read More »

340B INDUSTRY LEADER SPOTLIGHT

Anthony Velasquez, Chief Product Officer, PharmaForce

Anthony Velasquez
Q: Where did you grow up?

I was born in the Dominican Republic but grew up most of my life in Philadelphia, Pennsylvania. We moved a few times, but it was all within the city. The best memories I had growing up were playing sports at the park and on our block.

Read More »

PhRMA Makes its Case for Invalidating Arkansas’s First-of-its-Kind 340B Contract Pharmacy Law

PhRMA wordmark repeated on blue background
"There is no room for states, pharmacies, or other interests to step in and try to supplant” the federal government’s exclusive control over the 340B program, PhRMA told a federal district court in Arkansas late last week.

The 340B program “has always been uniquely federal in nature” and “there is no room for states, pharmacies, or other interests to step in and try to supplant” the federal government’s exclusive control over it, the brand drug industry said

Read More »

Amgen Announces Second Round of Refunds this Year for 340B Overcharges

Amgen wordmark on building facade
Drugmaker Amgen last week extended its existing 340B contract pharmacy restrictions to federal grantees.

Biotech company Amgen said last week it would pay refunds for 340B overcharges occurring in the third and fourth quarters of 2019.

The posting on the U.S. Health Resources and Services Administration website marks Amgen’s second 340B refund notice so far

Read More »

340B Pharmacy Services Company Avita Expands into Clinician and Support Staff Services

Michael Yount, Avita headshot
Maintaining regular access to providers is a challenge for many 340B grantee entities and can make it hard for them to leverage the 340B program, Avita CEO Michael Yount says.

Avita, a leading provider of 340B contract pharmacy and third-party administration services geared toward HIV and LGBTQ+ communities, is expanding into medical practice staffing and management.

Avita announced Oct. 5 that it has acquired HIV/AIDS, LGBTQ+, and primary care health

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live